title: Considering photodynamic therapy as a therapeutic modality in selected cases of dome-shaped macula complicated by foveal serous retinal detachment.
abstract: OBJECTIVE
  To study the role of photodynamic therapy (PDT) as a therapeutic modality in myopic patients with dome-shaped macula (DSM) associated with foveal serous retinal detachment (SRD).
  
  
  METHODS
  Retrospective interventional case series. The medical records of 10 consecutive myopic patients (10 eyes) with DSM associated with subfoveal SRD and treated with PDT were reviewed. Visual gain and loss were considered as increasing or decreasing of two or more lines of best corrected visual acuity (BCVA), respectively, and eyes with fluid resolution were deemed responsive to PDT.
  
  
  RESULTS
  All eyes underwent several PDT treatments, with a median of three and a median follow-up time of 15.5 months. At final follow-up, six eyes (60%) showed complete resolution of the foveal SRD. The baseline hypocyanescent macular area observed during late indocyanine green angiography (ICGA) frames was significantly lower in the group of patients who responded to PDT and had an increase of at least two Snellen lines in BCVA (P = .01).
  
  
  CONCLUSIONS
  Data suggest that myopic eyes associated with DSM and foveal SRD may be responsive to PDT, showing total resolution of fluid accumulation and positive BCVA changes if baseline ICGA findings show evidence of a limited hypocyanescent macular area.
authors.forename: Ilir
authors.initials: I
authors.lastname: Arapi
authors.forename: Piergiorgio
authors.initials: P
authors.lastname: Neri
authors.forename: Cesare
authors.initials: C
authors.lastname: Mariotti
authors.forename: Rosaria
authors.initials: R
authors.lastname: Gesuita
authors.forename: Vittorio
authors.initials: V
authors.lastname: Pirani
authors.forename: Francesco
authors.initials: F
authors.lastname: Freddo
authors.forename: Pajtim
authors.initials: P
authors.lastname: Lutaj
authors.forename: Alfonso
authors.initials: A
authors.lastname: Giovannini
mesh_terms: D000328:Adult; D000368:Aged; D004396:Coloring Agents; D004108:Dilatation, Pathologic; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005584:Fovea Centralis / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D007208:Indocyanine Green; D008266:Macula Lutea / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000150:complications; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use; D011166:Porphyrins / Q000627:therapeutic use; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012164:Retinal Diseases / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D012189:Retrospective Studies; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D000077362:Verteporfin; D014792:Visual Acuity / Q000502:physiology
chemical_list: D004396:Coloring Agents; D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin; D007208:Indocyanine Green